Started from 2016, ExcelMab has been focused on next generation of multi-specific antibody development, including T cell engagers for B cell malignancy, solid tumors and autoimmune diseases. We have several assets in clinical studies, which showed impressive efficacy and good safety profile. In addition, we have multiple PCC assets with BIC potential that are ready to collaboration. Our solid tumor assets are related to lung, prostate, ovarian, breast cancers.